Literature DB >> 21177283

Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules.

Richard L Wong1, Bai Liu, Xiaoyun Zhu, Lijing You, Lin Kong, Kai-Ping Han, Hyung-Il Lee, Pierre-Andre Chavaillaz, Moonsoo Jin, Yi Wang, Peter R Rhode, Hing C Wong.   

Abstract

Human interleukin-15 (hIL-15) and its receptor α (hIL-15Rα) are co-expressed in antigen presenting cells allowing trans-presentation of the cytokine to immune effector cells. We exploited the high-affinity interactions between hIL-15 and the extracellular hIL-15Rα sushi domain (hIL-15RαSu) to create a functional scaffold for the design of multispecific fusion protein complexes. Using single-chain T cell receptors (scTCRs) as recognition domains linked to the IL-15:IL-15Rα scaffold, we generated both bivalent and bispecific complexes. In these fusions, the scTCR domains retain the antigen-binding activity and the hIL-15 domain exhibits receptor binding and biological activity. As expected, bivalent scTCR fusions exhibited improved antigen binding due to increased avidity, whereas fusions comprising two different scTCR domains were capable of binding two cognate peptide/MHC complexes. Bispecific molecules containing scTCR and scCD8αβ domains also exhibit enhanced binding to peptide/MHC complexes, demonstrating that the IL-15:IL-15Rα scaffold displays flexibility necessary to support multi-domain interactions with a given target. Surprisingly, functional heterodimeric molecules could be formed by co-expressing the TCR α and β chains separately as fusions to the hIL-15 and hIL-15RαSu domains. Together, these properties indicate that the hIL-15 and hIL-15RαSu domains can be used as versatile, functional scaffold for generating novel targeted immune molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177283      PMCID: PMC3049345          DOI: 10.1093/protein/gzq116

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  53 in total

1.  Molecular applications of fusions to leucine zippers.

Authors:  J D Rieker; J C Hu
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo.

Authors:  M Orchardson; J A Gracie; B P Leung; H Guan; W Niedbala; G K Paterson; I B McInnes; F Y Liew
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  Expression, purification, and functional analysis of murine ectodomain fragments of CD8alphaalpha and CD8alphabeta dimers.

Authors:  P Kern; R E Hussey; R Spoerl; E L Reinherz; H C Chang
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

4.  CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.

Authors:  Martha S Hayden-Ledbetter; Chuck G Cerveny; Erik Espling; William A Brady; Laura S Grosmaire; Philip Tan; Robert Bader; Sonya Slater; Christy A Nilsson; Dauphine S Barone; Alexander Simon; Cheryl Bradley; Peter A Thompson; Alan F Wahl; Jeffrey A Ledbetter
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

5.  Novel human interleukin-15 agonists.

Authors:  Xiaoyun Zhu; Warren D Marcus; Wenxin Xu; Hyung-il Lee; Kaiping Han; Jack O Egan; Jason L Yovandich; Peter R Rhode; Hing C Wong
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

6.  Targeting activity of a TCR/IL-2 fusion protein against established tumors.

Authors:  Jinghai Wen; Xiaoyun Zhu; Bai Liu; Lijing You; Lin Kong; Hyung-Il Lee; Kai-Ping Han; Jeffrey L Wong; Peter R Rhode; Hing C Wong
Journal:  Cancer Immunol Immunother       Date:  2008-03-28       Impact factor: 6.968

7.  E. coli expression and purification of human and cynomolgus IL-15.

Authors:  Alison Ward; Malcolm Anderson; Robert I Craggs; Justine Maltby; Caroline Grahames; Rick A Davies; Donna Finch; Debbie Pattison; Heather Oakes; Philip R Mallinder
Journal:  Protein Expr Purif       Date:  2009-05-10       Impact factor: 1.650

8.  Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.

Authors:  Shicheng Yang; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

9.  Construction and production of an IgG-like tetravalent bispecific antibody for enhanced therapeutic efficacy.

Authors:  Dan Lu; Zhenping Zhu
Journal:  Methods Mol Biol       Date:  2009

10.  In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences.

Authors:  Angel M Cuesta; David Sánchez-Martín; Laura Sanz; Jaume Bonet; Marta Compte; Leonor Kremer; Francisco J Blanco; Baldomero Oliva; Luis Alvarez-Vallina
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

View more
  7 in total

1.  IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.

Authors:  Kai-ping Han; Xiaoyun Zhu; Bai Liu; Emily Jeng; Lin Kong; Jason L Yovandich; Vinay V Vyas; Warren D Marcus; Pierre-Andre Chavaillaz; Christian A Romero; Peter R Rhode; Hing C Wong
Journal:  Cytokine       Date:  2011-10-22       Impact factor: 3.861

Review 2.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

3.  Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Authors:  Jennifer D Stone; Adam S Chervin; Hans Schreiber; David M Kranz
Journal:  Biotechnol Prog       Date:  2012-10-18

4.  A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.

Authors:  Bai Liu; Lin Kong; Kaiping Han; Hao Hong; Warren D Marcus; Xiaoyue Chen; Emily K Jeng; Sarah Alter; Xiaoyun Zhu; Mark P Rubinstein; Sixiang Shi; Peter R Rhode; Weibo Cai; Hing C Wong
Journal:  J Biol Chem       Date:  2016-09-20       Impact factor: 5.157

5.  Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Authors:  Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-13       Impact factor: 5.742

6.  Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis.

Authors:  Tom H M Ottenhoff; Ranjeeta Hari Dass; Ninghan Yang; Mingzi M Zhang; Hazel E E Wong; Edhyana Sahiratmadja; Chiea Chuen Khor; Bachti Alisjahbana; Reinout van Crevel; Sangkot Marzuki; Mark Seielstad; Esther van de Vosse; Martin L Hibberd
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

Review 7.  Immunotherapy of Childhood Sarcomas.

Authors:  Stephen S Roberts; Alexander J Chou; Nai-Kong V Cheung
Journal:  Front Oncol       Date:  2015-08-07       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.